Research ExplorerPublicationsNCI First International Workshop on the Biology, Prevention,...

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Standard

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. / Porter, David L; Alyea, Edwin P; Antin, Joseph H; DeLima, Marcos; Estey, Eli; Falkenburg, J H Frederik; Hardy, Nancy; Kröger, Nicolaus; Leis, Jose; Levine, John; Maloney, David G; Peggs, Karl; Rowe, Jacob M; Wayne, Alan S; Giralt, Sergio; Bishop, Michael R; van Besien, Koen.

In: BIOL BLOOD MARROW TR, Vol. 16, No. 11, 11, 01.11.2010, p. 1467-1503.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Porter, DL, Alyea, EP, Antin, JH, DeLima, M, Estey, E, Falkenburg, JHF, Hardy, N, Kröger, N, Leis, J, Levine, J, Maloney, DG, Peggs, K, Rowe, JM, Wayne, AS, Giralt, S, Bishop, MR & van Besien, K 2010, 'NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.', BIOL BLOOD MARROW TR, vol. 16, no. 11, 11, pp. 1467-1503. https://doi.org/10.1016/j.bbmt.2010.08.001

APA

Porter, D. L., Alyea, E. P., Antin, J. H., DeLima, M., Estey, E., Falkenburg, J. H. F., Hardy, N., Kröger, N., Leis, J., Levine, J., Maloney, D. G., Peggs, K., Rowe, J. M., Wayne, A. S., Giralt, S., Bishop, M. R., & van Besien, K. (2010). NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. BIOL BLOOD MARROW TR, 16(11), 1467-1503. [11]. https://doi.org/10.1016/j.bbmt.2010.08.001

Vancouver

Porter DL, Alyea EP, Antin JH, DeLima M, Estey E, Falkenburg JHF et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. BIOL BLOOD MARROW TR. 2010 Nov 1;16(11):1467-1503. 11. https://doi.org/10.1016/j.bbmt.2010.08.001

Bibtex

@article{7e33a3c09bf44323a53287e9f1e673cf,
title = "NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.",
abstract = "Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT). Treatment options for relapse have been inadequate, and the majority of patients ultimately die of their disease. There is no standard approach to treating relapse after alloHSCT. Withdrawal of immune suppression and donor lymphocyte infusions are commonly used for all diseases; although these interventions are remarkably effective for relapsed chronic myelogenous leukemia, they have limited efficacy in other hematologic malignancies. Conventional and novel chemotherapy, monoclonal antibody therapy, targeted therapies, and second transplants have been utilized in a variety of relapsed diseases, but reports on these therapies are generally anecdotal and retrospective. As such, there is an immediate need for well-designed, disease-specific trials for treatment of relapse after alloHSCT. This report summarizes current treatment options under investigation for relapse after alloHSCT in a disease-specific manner. In addition, recommendations are provided for specific areas of research necessary in the treatment of relapse after alloHSCT.",
keywords = "Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Hodgkin Disease, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphocyte Transfusion, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasm Recurrence, Local, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Transplantation, Homologous, Treatment Failure",
author = "Porter, {David L} and Alyea, {Edwin P} and Antin, {Joseph H} and Marcos DeLima and Eli Estey and Falkenburg, {J H Frederik} and Nancy Hardy and Nicolaus Kr{\"o}ger and Jose Leis and John Levine and Maloney, {David G} and Karl Peggs and Rowe, {Jacob M} and Wayne, {Alan S} and Sergio Giralt and Bishop, {Michael R} and {van Besien}, Koen",
note = "Copyright {\textcopyright} 2010 American Society for Blood and Marrow Transplantation. All rights reserved.",
year = "2010",
month = nov,
day = "1",
doi = "10.1016/j.bbmt.2010.08.001",
language = "English",
volume = "16",
pages = "1467--1503",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "11",

}

RIS

TY - JOUR

T1 - NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

AU - Porter, David L

AU - Alyea, Edwin P

AU - Antin, Joseph H

AU - DeLima, Marcos

AU - Estey, Eli

AU - Falkenburg, J H Frederik

AU - Hardy, Nancy

AU - Kröger, Nicolaus

AU - Leis, Jose

AU - Levine, John

AU - Maloney, David G

AU - Peggs, Karl

AU - Rowe, Jacob M

AU - Wayne, Alan S

AU - Giralt, Sergio

AU - Bishop, Michael R

AU - van Besien, Koen

N1 - Copyright © 2010 American Society for Blood and Marrow Transplantation. All rights reserved.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT). Treatment options for relapse have been inadequate, and the majority of patients ultimately die of their disease. There is no standard approach to treating relapse after alloHSCT. Withdrawal of immune suppression and donor lymphocyte infusions are commonly used for all diseases; although these interventions are remarkably effective for relapsed chronic myelogenous leukemia, they have limited efficacy in other hematologic malignancies. Conventional and novel chemotherapy, monoclonal antibody therapy, targeted therapies, and second transplants have been utilized in a variety of relapsed diseases, but reports on these therapies are generally anecdotal and retrospective. As such, there is an immediate need for well-designed, disease-specific trials for treatment of relapse after alloHSCT. This report summarizes current treatment options under investigation for relapse after alloHSCT in a disease-specific manner. In addition, recommendations are provided for specific areas of research necessary in the treatment of relapse after alloHSCT.

AB - Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT). Treatment options for relapse have been inadequate, and the majority of patients ultimately die of their disease. There is no standard approach to treating relapse after alloHSCT. Withdrawal of immune suppression and donor lymphocyte infusions are commonly used for all diseases; although these interventions are remarkably effective for relapsed chronic myelogenous leukemia, they have limited efficacy in other hematologic malignancies. Conventional and novel chemotherapy, monoclonal antibody therapy, targeted therapies, and second transplants have been utilized in a variety of relapsed diseases, but reports on these therapies are generally anecdotal and retrospective. As such, there is an immediate need for well-designed, disease-specific trials for treatment of relapse after alloHSCT. This report summarizes current treatment options under investigation for relapse after alloHSCT in a disease-specific manner. In addition, recommendations are provided for specific areas of research necessary in the treatment of relapse after alloHSCT.

KW - Hematologic Neoplasms

KW - Hematopoietic Stem Cell Transplantation

KW - Hodgkin Disease

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell

KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive

KW - Leukemia, Myeloid, Acute

KW - Lymphocyte Transfusion

KW - Lymphoma, Non-Hodgkin

KW - Multiple Myeloma

KW - Neoplasm Recurrence, Local

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma

KW - Recurrence

KW - Transplantation, Homologous

KW - Treatment Failure

U2 - 10.1016/j.bbmt.2010.08.001

DO - 10.1016/j.bbmt.2010.08.001

M3 - SCORING: Journal article

C2 - 20699125

VL - 16

SP - 1467

EP - 1503

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 11

M1 - 11

ER -